| SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria |
|
Expert Review of Clinical Pharmacology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| How we diagnose Myelodysplastic syndromes |
|
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Germline variants in acquired aplastic anemia: current knowledge and future perspectives |
|
Haematologica |
Aplastic Anemia |
| Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
|
Pediatric Blood Cancer |
Aplastic Anemia, Pediatric |
